Novo NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for type II diabetes [T2D]), Rybelsus (for T2D) and Wegovy (for obesity). Since launch, Novo has steadily expanded the commercial opportunity for both Ozempic and Wegovy through multiple label expansions. Together, the drugs generated approximately DKK 112.2 billion in the first half of 2026, accounting for about 75.5% of NVO's adjusted sales. Investors will be particularly interested in the sales numbers for these two drugs when Novo reports third-quarter 2026 results on Nov. 4. Novo has also broadened its oral semaglutide franchise.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.